
The original instrument and the following digest, which constitutes no part of the legislative instrument, were prepared by Senate Legislative Services. The keyword, summary, and digest do not constitute part of the law or proof or indicia of legislative intent. [R.S. 1:13(B) and 24:177(E)]

SB 43 Engrossed

DIGEST
2026 Regular Session

McMath

Proposed law establishes the Psychedelic-Assisted Therapy Program within the La. Dept. of Health, office of behavioral health.

Proposed law establishes the following purposes of the program:

- (1) To identify academic health centers conducting clinical studies for the use of psychedelic-assisted therapy involving ibogaine and psilocybin for the treatment of opioid use disorders, co-occurring substance use disorders, and treatment-resistant neurological or mental health conditions.
- (2) To utilize the human service districts and authorities to identify eligible participants and to establish a process to allow parishes to utilize opioid settlement funds to enroll eligible patients residing in the parish to participate in the studies.
- (3) To allow parishes to utilize opioid settlement funds to enroll eligible patients residing in the parish to participate in the studies.

Proposed law authorizes the department to seek and receive federal funds, gifts, grants, and donations for the program in addition to utilizing opioid settlement funds.

Proposed law requires participating academic health centers to submit an annual progress report to the department and requires the department to submit a compiled report to the legislature by Feb. 1st of each year.

Proposed law requires the department and participating academic health centers to coordinate with other states that are conducting clinical trials for use of psychedelic-assisted therapy to the extent feasible.

Proposed law authorizes academic health centers to enter into agreements with drug developers to establish a consortium for purposes of conducting drug development clinical trials with ibogaine and provides for the process to establish a consortium.

Proposed law provides for the distribution of any revenue attributable to intellectual property rights and other commercial rights arising from drug development clinical trial.

Effective August 1, 2026.

(Adds R.S. 28:211 and 212)

Summary of Amendments Adopted by Senate

Committee Amendments Proposed by Senate Committee on Health and Welfare to the original bill

1. Changes requirements relative to the La. Dept. of Health's role in overseeing the clinical trials.
2. Changes requirements relative to required documentation for academic health centers conducting trials.
3. Authorizes academic health centers to enter into agreements with drug developers to conduct ibogaine clinical trials and participate in a consortium with other states.